Related references
Note: Only part of the references are listed.Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
The Preoperative Neutrophil-Lymphocyte Ratio Predicts Recurrence and Survival Among Patients Undergoing R0 Resections of Adenocarcinomas of the Esophagogastric Junction
Dawei Yuan et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Inflammatory chemokines and metastasis-tracing the accessory
L. Borsig et al.
ONCOGENE (2014)
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
Suee Lee et al.
BMC CANCER (2013)
Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy
Hailong Jin et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Neoadjuvant Treatment for Gastric Cancer
Christoph Schuhmacher et al.
JOURNAL OF GASTRIC CANCER (2013)
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
Eran Elinav et al.
NATURE REVIEWS CANCER (2013)
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
Ki Han Kim et al.
BIOMARKERS (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Elevated Preoperative Neutrophil to Lymphocyte Ratio Predicts Poor Survival Following Resection in Late Stage Gastric Cancer
Mi Ran Jung et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer
Hideaki Shimada et al.
GASTRIC CANCER (2010)
The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment
Mehmet Aliustaoglu et al.
MEDICAL ONCOLOGY (2010)
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors
Chiara Carlomagno et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2010)
Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis
Hee Yeon Seo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin
Xiaodong Zhu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer
Takeharu Yamanaka et al.
ONCOLOGY (2007)
A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer
Sung Yong Oh et al.
ACTA ONCOLOGICA (2007)
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
F De Vita et al.
BRITISH JOURNAL OF CANCER (2005)
The logrank test
JM Bland et al.
BRITISH MEDICAL JOURNAL (2004)
Share Paper
